Skip to content

Psychedelic-assisted therapy: all studies

Page 228 of 294: studies 2,271 to 2,280 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

Quantitative, qualitative and located therapeutic experiences with psilocibious fungal microdosis

Salud Ciencia y Tecnología - Serie de Conferencias April 24, 2023 Nicolás Valente, Luis E. Acosta, Nadia Piazza et al.

In a context of popularization and boom of the use and research of psychedelic therapies worldwide, the therapeutic use of psilocibious fungi has gained massiveness. Its two main modalities, macrodosis (occasional use of sufficient doses to produce deep perceptual, physiological and psychological effects) and microdosis (use of dose low enough to allow the development of the person in daily...

Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users

Frontiers in Psychiatry April 14, 2023 Jennifer L. Jones 4 citations

BackgroundAlcohol and other substance use disorders are commonly associated with post-traumatic stress disorder (PTSD), and the presence of these comorbidities is associated with worse treatment outcomes. Additionally, disparities in substance and PTSD prevalence have been associated with minority races and ethnicities, and minorities have been shown to be less likely to engage in treatment....

DOI: 10.3389/fpsyt.2023.1096298 (opens in new tab) Full text (opens in new tab) MDMA Race and ethnicity Viable treatment option Therapeutic potential +4

Psychedelic therapies are returning to psychiatry

Open Access Government April 12, 2023 Erika Dyck

Psychedelic therapies are returning to psychiatry Professor Erika Dyck, Canada Research Chair in History of Health & Social Justice at the University of Saskatchewan argues that psychedelic drugs and therapies, whether conducted in ceremonial settings or clinical ones, are being touted as life-changing moments for their capacity to efficiently transform an individual's perspective on...

O uso de agentes psicodélicos no tratamento da dependência de álcool e tabaco: revisão integrativa

SMAD Revista Eletrônica Saúde Mental Álcool e Drogas (Edição em Português) April 10, 2023 Eduarda Medrado Araújo Borges, Glauber Carvalho Barbosa, Alyce Maryana Costa Araújo et al.

Objetivo: analisar os estudos que abordam o o uso deagentes psicodélicos no tratamento da dependência de álcoole tabaco no contexto nacional e internacional. Método:revisão integrativa na Literatura Latino-Americana e do Caribeem Ciências da Saúde (LILACS), Medical Literature Analysisand Retrievel System Online (Medline), Scientific EletronicLibrary Online (SciELO), EBSCO e PubMed,...

The Road to Ixtlan in Neuro-Degenerative Diseases Is Paved with Palliative Cobblestones

AJOB Neuroscience April 3, 2023 Christopher Poppe, Manuel Trachsel

Aday, J. S., C. C. Davoli, and E. K. Bloesch. 2019. 2018: A watershed year for psychedelic science. Drug Science, Policy and Law 5. doi:10.1177/2050324519872284. Chapman, M., J. Philip, and P. Komesaroff. 2019. Towards an ecology of dementia: A manifesto. Journal of Bioethical Inquiry 16 (2):209–16. doi:10.1007/s11673-01909910-8. Cunningham, C., S. Macfarlane, and H. Brodaty. 2019. Language...

Avoiding the Premature Introduction of Psychedelic Medicines in Alzheimer’s Disease and Related Disorders

AJOB Neuroscience April 3, 2023 A. Carter, Myfanwy Graham, W. Hall et al.

informed consent to psychedelic-assisted psychotherapy. Johnson, M. W. 2021. Consciousness, religion, and gurus: Pitfalls of psychedelic medicine. ACS Pharmacology & Translational Science 4 (2):578–81. doi:10.1021/acsptsci. 0c00198. Herzberg, G., K. Conour, J. Butler, A. Emerson, L. S. Gillooly, V. Gold, M. Hayes, L. Mix, and E. Sienknecht. 2019. Towards an ethos of equity and inclusion in the...

Barriers and Facilitators to the Equitable Access of Psychedelic Medical Care and Research in Alzheimer’s Disease and Related Dementias

AJOB Neuroscience April 3, 2023 Kai Rudolph

Beauchamp, T. L., and J. F. Childress. 2019. Principles of biomedical ethics. Oxford: Oxford University Press. Boyle, J. 2004. Medical ethics and double effect: the case of terminal sedation. Theoretical Medicine and Bioethics 25 (1):51–60. doi:10.1023/b:meta.0000025096.25317.22. Creutzfeldt, C. J., B. M. Kluger, and R. G. Holloway. 2019. Neuropalliative care: A guide to improving the lives of...

Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective

Frontiers in Psychology April 3, 2023 Daniel Meling, Milan Scheidegger 17 citations

Psychedelics are psychoactive substances that receive renewed interest from science and society. Increasing empirical evidence shows that the effects of psychedelics are associated with alterations in biochemical processes, brain activity, and lived experience. Still, how these different levels relate remains subject to debate. The current literature presents two influential views on the...

DOI: 10.3389/fpsyg.2023.1100058 (opens in new tab) Perspective graphical Causality physics Autonomy Epistemology +4

Ketamine-assisted meaning-centered psychotherapy for a patient with severe suicidal behavior

Palliative & Supportive Care April 1, 2023 Fernando Espí Forcén, Laura Marengo, Maya Behn

AbstractThere is a current debate in society as to whether depression can be a terminal illness. Meaning-centered psychotherapy (MCP) and psychedelic medicines have both been shown to treat existential distress in palliative care settings. We are reporting the case of a patient for whom MCP combined with ketamine was an effective treatment for his recurrent and severe depressive disorder with...

Gli psichedelici: quanto è efficace e sicuro il loro possibile impiego in psichiatriae psicoterapia? Lo stato delle evidenze

PNEI REVIEW April 1, 2023 Francesco Dente

Nell'ultimo decennio la ricerca sull'utilizzo terapeutico degli psichedelici ha subito un'impennata, soprattutto per quanto riguarda la loro poten- ziale applicazione nel trattamento dei disturbi psichiatrici. In questi studi è stata indagata la sicurezza e l'efficacia delle varie sostanze psichedeliche, come gli psichedelici classici (psilocibina, ayahuasca e LSD) la ketamina e l'MDMA. Gli...